+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4857393
  • Report
  • October 2019
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Ardelyx Inc
  • Emmaus Life Sciences
  • GlyPharma Therapeutics
  • ia Pharmaceuticals
  • Merck KGaA
  • Nutrinia Ltd
  • MORE
The report on the global short bowel syndrome market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global short bowel syndrome market to grow with a CAGR of 21.0% over the forecast period from 2019-2025. The study on short bowel syndrome market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on short bowel syndrome market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global short bowel syndrome market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global short bowel syndrome market over the period of 2017 to 2025. Further, the Growth Matrix given in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings:

1. Drivers
  • Rapid development in the field of healthcare
2. Restraints
  • Lack of approved treatment options
3. Opportunities
  • On-profit organizations are promoting research & development around short bowel syndrome
Research Methodology

A. Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include:

1. Key Opinion Leaders associated with the publisher
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B. Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global short bowel syndrome market is segmented on the basis of drug class.

The Global Short Bowel Syndrome Market by Drug Class
  • GLP-2
  • Growth Hormone
  • Glutamine
  • Others
Company Profiles

The companies covered in the report include
  • Nutrinia Ltd
  • Emmaus Life Sciences
  • Shire plc
  • Merck KGaA
  • OxThera
  • GlyPharma Therapeutics
  • Ardelyx Inc
  • Sancilio & Company Inc
  • Zealand Pharma A/S
  • Naia Pharmaceuticals
What does this report deliver?

1. Comprehensive analysis of the global as well as regional markets of the short bowel syndrome market.
2. Complete coverage of all the segments in the short bowel syndrome market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global short bowel syndrome market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ardelyx Inc
  • Emmaus Life Sciences
  • GlyPharma Therapeutics
  • ia Pharmaceuticals
  • Merck KGaA
  • Nutrinia Ltd
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Short Bowel Syndrome Market Highlights
2.2. Short Bowel Syndrome Market Projection
2.3. Short Bowel Syndrome Market Regional Highlights

3. Global Short Bowel Syndrome Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Drug Class
3.4.2. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Short Bowel Syndrome Market

4. Short Bowel Syndrome Market Macro Indicator Analysis

5. Global Short Bowel Syndrome Market by Drug Class
5.1. GLP-2
5.2. Growth Hormone
5.3. Glutamine
5.4. Others

6. Global Short Bowel Syndrome Market by Region 2019-2025
6.1. North America
6.1.1. North America Short Bowel Syndrome Market by Drug Class
6.1.2. North America Short Bowel Syndrome Market by Country
6.2. Europe
6.2.1. Europe Short Bowel Syndrome Market by Drug Class
6.2.2. Europe Short Bowel Syndrome Market by Country
6.3. Asia-Pacific
6.3.1. Asia-Pacific Short Bowel Syndrome Market by Drug Class
6.3.2. Asia-Pacific Short Bowel Syndrome Market by Country
6.4. RoW
6.4.1. RoW Short Bowel Syndrome Market by Drug Class
6.4.2. RoW Short Bowel Syndrome Market by Sub-region

7. Company Profiles and Competitive Landscape
7.1. Competitive Landscape in the Global Short Bowel Syndrome Market
7.2. Companies Profiled
7.2.1. Nutrinia Ltd
7.2.2. Emmaus Life Sciences
7.2.3. Shire plc
7.2.4. Merck KGaA
7.2.5. OxThera
7.2.6. GlyPharma Therapeutics
7.2.7. Ardelyx Inc
7.2.8. Sancilio & Company Inc
7.2.9. Zealand Pharma A/S
7.2.10. Naia Pharmaceuticals

8. Appendix
8.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Nutrinia Ltd
  • Emmaus Life Sciences
  • Shire plc
  • Merck KGaA
  • OxThera
  • GlyPharma Therapeutics
  • Ardelyx Inc
  • Sancilio & Company Inc
  • Zealand Pharma A/S
  • ia Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll